Previous close | 44.90 |
Open | N/A |
Bid | 45.00 |
Ask | 46.45 |
Strike | 115.00 |
Expiry date | 2025-01-17 |
Day's range | 44.90 - 44.90 |
Contract range | N/A |
Volume | |
Open interest | N/A |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.